−  1 − © 2015 ZS Associates | CONFIDENTIAL ASCO 2015 Overview Infographic_V2

399 1,356 947

#ASCO15 TWITTER COVERAGE

6,87

7

14,5

91

15,1

63

May 29-June 2, 2015

13,6

68

6,57

2

ASCO 2015 TOTAL TWEETS

56,871

FRI

SAT SUN MON

TUE

ASCO 2015 TOP TUMOR TYPES

WORLD WIDE REACH

2014 2015

14Mn 44Mn

Lung Cancer

Breast Cancer

Melanoma

Lymphoma

Multiple Myeloma

1.6X MORE HCPs POSTED ABOUT ASCO 2015 AS COMPARED TO LAST YEAR 87

8

458

423

1.3K 2.1K

2014

2015

317

408

TOP 5 INFLUENTIAL HCPs (Driving Trending Conversations)

@mtmdphd (Mike Thompson) @subatomicdoc (Matthew Katz)

@fischmd (Michael Fisch) @drattai (Deanna Attai)

@drdonsdizon

RTs

COVERAGE BY HCPs

126 119

71

51

70

TOP POSTS BY HCPs (Health Care Professionals) (Driving the maximum number of Retweets)

KEY STAKEHOLDERS 28% OF THE TWEETS ABOUT ASCO 2015 WERE BY HCPs

On avg. each HCP posted 8 tweets around ASCO 2015 2X more than other stakeholders

Impact where it matters

Follow us on Twitter @ZSAssociates

5,762

3,523

1,961

1,790

1,627 INCREASE IN TOTAL TWEETS OVER LAST YEAR 2X

NO. OF TWEETS AROUND KEY ASCO THEMES

Immunotherapy Cost Value Price 2,673

(Don S Dizon)

−  1 − © 2015 ZS Associates | CONFIDENTIAL

Lung Cancer Infographic New

LUNG CANCER ASCO 2015

LUNG CANCER TWITTER VOLUME TRENDS

T W I T T E R C O V E R A G E

LUNG CANCER AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON LUNG CANCER

647

280

164

65

CheckMate 057

CheckMate 017

AURA Study

KEYNOTE-028

HCP SENTIMENT AROUND KEY STUDIES ON LUNG CANCER

Follow us on Twitter @ZSAssociates

Impact where it matters.

STEVEN EISENBERG

1.3K

@n8pennell

49

JACK WEST

7.6K

@jackwestmd

60

MATTHEW KATZ

10.6K

@subatomicdoc

63

NAOTO UENO

8.6K

@teamoncology

46

MIKE THOMPSON

8.5K

@mtmdphd

53

ROBERT WEST

16.6K

@westr

53 NA

67% of  HCPs  …  

HCPs were concerned that a low percentage of patients were eligible for the PD-L1+ based trial

621

1,532 2,013

1,159 437

MAY 29 MAY 30 MAY 31 JUNE 1 JUNE 2

ASCO 2015

1,510

5,762

4x Increase in number of tweets about lung cancer

HCPs Companies

Support Groups

Patients Others**

Media

21% 7%

2%

5%

4% 48%

Commu- nicators*

11%

2%

Institutions

*Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group

Ph III Non-squamous: Nivolumab vs. Docetaxel

Ph I EGFR-T790M mutation: AZD9291

Ph III Squamous: Nivolumab vs. Docetaxel

Ph Ib SCLC: Pembrolizumab

KEYNOTE- 028 Overall Response rate of 35% was considered promising by HCPs

BIOMARKERS

174

NSCLC 1,135

(By number of tweets)

SCLC

TYPES OF LUNG CANCER (By number of tweets)

CheckMate 057

CheckMate 017

AURA Study

KEYNOTE 028

A neutral score indicates that the study was mentioned without any sentiment

25%

67%

8%

Twitter Followers

Klout Score

TOP INFLUENTIAL HCPs FOR LUNG CANCER

12%

62% 27%

Num

ber o

f tw

eets

19%

76%

5%

31% 64%

5%

Mixed reaction in HCPs about the study due to improved outcomes in PD-L1+ patients only

... tweeting about the CheckMate 057 trial were impressed by the Overall Survival

HCPs were excited about adopting Nivo as the 2L non-squam standard of care

ASCO 2014

(By number of tweets)

Squamous 297 515

154 PD-L1 EGFR ALK T790M

84 232

313

Non-Squamous

−  1 − © 2015 ZS Associates | CONFIDENTIAL

Lung Cancer Infographic New

34%

66%

BREAST CANCER ASCO 2015

T W I T T E R C O V E R A G E

293

880 648 1,270

432

MAY 29 MAY 30 MAY 31 JUNE 1 JUNE 2

HCPs Companies

Support Groups

Patients Others**

Media

21% 8%

3%

6%

4% 44%

343

193

83

75

PALOMA-3

NSABP B-35

ExteNET

MARIANNE

NSABP B-35

ExteNET

31%

69%

14%

14%

72%

54%

14% 32%

PALOMA-3

66% of HCPs .. …  tweeting  about  the  PALOMA-3 study appreciated the improved PFS

Anastrozole's better Breast Cancer free survival rate and fewer side effects than Tamoxifen were discussed widely

8.8K 8.7K 12.3K 10.8K 13K 9.3K

DEANNA ATTAI

@drattai

NAOTO UENO

@teamoncology

MIKE THOMPSON

@mtmdphd

Follow us on Twitter @ZSAssociates

Impact where it matters.

KEY ASCO BREAST CANCER THEMES

179

Surgical Approaches TNBC

215 66 165

(By number of tweets)

ASCO 2014

ASCO 2015

2,023 3,523

73 %

Increase in number of tweets about Breast Cancer

MARIANNE

JOHN CROWN

@ProfJohnCrown

MICHAEL FISCH

@fischmd

MATTHEW KATZ

@subatomicdoc

56 59 67 63 50 65

NSABP B-35

TOXICITY DFS

Neratinib was seen to offer minimal benefit when weighed against its toxicity

ExteNET study

Commu-nicators*

12%

2%

Institutions

Num

ber o

f tw

eets

A neutral score indicates that the study was mentioned without any sentiment

*Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group The MDV3100-11 (enzalutamide) trial received

minimal coverage, with only 17 tweets

Genetic Testing Survivorship

Twitter Followers

Klout Score

Ph III: (palbociclib + fulvestrant) vs. (placebo + fulvestrant)

Ph III: (RT* + anastrozole) vs. (RT* + tamoxifen)

Ph III: neratinib vs. placebo

(T-DM1 + placebo) vs. (T-DM1 + pertuzumab) vs. (trastuzumab + taxane)

Ph III

BREAST CANCER TWITTER VOLUME TRENDS

BREAST CANCER AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON BREAST CANCER (By number of tweets)

HCP SENTIMENT AROUND KEY STUDIES ON BREAST CANCER

TOP INFLUENTIAL HCPs FOR BREAST CANCER

*Radiation Therapy

−  1 − © 2015 ZS Associates | CONFIDENTIAL Melanoma Infographic Re

MELANOMA ASCO 2015

MELANOMA TWITTER VOLUME TRENDS

T W I T T E R C O V E R A G E

MELANOMA AUTHOR CATEGORIZATION KEY CLINICAL STUDIES ON MELANOMA

799 CheckMate 067/069 nivolumab + Ipilimumab

48 KEYNOTE 001 pembrolizumab

HCP SENTIMENT AROUND KEY STUDIES ON MELANOMA

Impact where it matters.

50% of HCPs .. …  who  tweeted  about  Melanoma mentioned the Nivolumub + Ipilimumab study

KEY ASCO MELANOMA THEMES

204 60 Survival Cost

Follow us on Twitter @ZSAssociates

TOP INFLUENTIAL HCPs FOR MELANOMA

HCPs Companies

Support Groups

Patients Others**

Media

25% 7%

2%

6%

5% 44%

Communicators*

10%

1%

Institutions

MAY 30 MAY 31 JUNE 1 JUNE 2 MAY 29

81 414

847

338 281 N

umbe

r of t

wee

ts

KEYNOTE 001

74%

36%

27%

73%

A neutral score indicates that the study was mentioned without any sentiment

ASCO 2014

ASCO 2015

542 1,961

3.6x Increase in number of tweets about Melanoma

…around  the  Nivolumab + Ipilmumab, driven most frequently by HCPs appreciating the increased PFS PFS increased to

73% positive sentiment..

…for  Pembrolizumab, was mostly due to favorable reactions to the durability of response in metastatic patients KEYNOTE-001

36% positive sentiment..

*Authors who tweeted frequently about health care topics **Authors who cannot be classified into any major stakeholder group

21 PD-L1

Testing

(By number of tweets)

(By number of tweets)

(By number of tweets)

Twitter Followers

Klout Score

MIKE THOMPSON

8.7K

@mtmdphd

Prof. JOHN CROWN

13.1K

@ProfJohnCrown

ERIN D WHITMAN

2.5K

@melanoma_doctor

OLIVIER BRANFORD

19.4K

@olivierbranford

MICHEAL FISCH

12.4K

@fischmd

CheckMate 067/069

CheckMate 067/069

NA 65 59 56 NA